Tiziana Life Sciences Executive Chairman Increases Stake via Share Purchase

On June 15, 2026, Tiziana Life Sciences Ltd announced that its Executive Chairman and Founder, Mr. Gabriele Cerrone, increased his equity stake in the company. Through Panetta Partners Ltd, an entity in which he holds a beneficial interest, Mr. Cerrone purchased 15,000 common shares at a price of $1.11 per share. Following this transaction, his total holding reached 44,772,230 common shares, representing approximately 34.89% of the company's issued share capital. The filing also provided an update on the company's lead development candidate, foralumab, a fully human anti-CD3 monoclonal antibody. Foralumab is currently being evaluated in an open-label Expanded Access Program and a Phase 2a randomized, double-blind, placebo-controlled trial for patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS). To date, the Expanded Access Program has shown disease improvement or stability in all 14 dosed patients within six months. Tiziana continues to focus on its intranasal immunotherapy delivery platform for neuroinflammatory and neurodegenerative diseases.